Mandate

Vinge advises Zellis Group, a portfolio company of Apax Partners, in connection with the acquisition of Benify

Vinge has, together with Kirkland & Ellis, advised Zellis Group, a portfolio company of funds advised by Apax Partners LLP (“Apax”), in connection with the acquisition of Benify, a provider of employee benefits administration software, from Vitruvian Partners and the other shareholders.

As part of the transaction, Benify will be combined with Zellis Group’s benefits administration and employee engagement software business, Benefex, and Vitruvian Partners will become a minority investor in the Zellis Group alongside the Apax Funds. Together, Benefex and Benify will create a leading global benefits, reward, recognition, and employee engagement software provider with an enhanced value proposition to customers globally. Completion of the transaction is subject to customary closing conditions.

Vinge’s team consisted of among others Jonas Bergström, Anna Jonsson, Nicolas Ek, Johan Severinsson and Gustav Bergengren (M&A), Nils Unckel and Anton Sjökvist (Financial Regulatory), Albert Wållgren and Arvid Weimers (Banking and Finance), Oskar Larsson (Commercial Contracts) and Emelie Svensäter Jerntorp and Carolina Lundh (Employment).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025